Pharmaceutical company Sunshine Biopharma’s HMEC study has indicated the non-toxicity of anticancer compound Adva-27a to healthy tissue at high concentrations.

According to the data, concentrations of up to 24 micromolar of Adva-27a did not measurably inhibit the normal growth process of these cells.

"According to the data, concentrations of up to 24 micromolar of Adva-27a did not measurably inhibit the normal growth process of these cells."

Sunshine Biopharma CEO Dr Steve Slilaty said the data indicates the non-toxicity of Adva-27a to healthy tissue.

"This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy," Slilaty said.

The company completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a was measured in the HMEC cell line.

HMEC are non-cancerous human mammary epithelial cells isolated from reduction mammoplasty tissu,e and HMEC is the standard cell line used for ascertain the molecular and biochemical basis for in-vitro toxicity of drug candidates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adva-27a has previously established efficacy at killing different types of multidrug resistant cancer cell lines, such as MES-SA/Dx5, a Uterine Sarcoma cell line, MCF-7/MDR, a breast cancer cell line and H69AR, a small-cell lung cancer cell line.